

Cancer Center of Boston

[View the current Cancer Center of Boston Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocorporate/20391-Cancer+Center+of+Boston.html>)

Contact Details:

61 Lincoln St. Suite 307

Framingham

Massachusetts

01702

United States of America

Tel: 617-739-6605

Fax: 617-739-4819

Email: mbern@cancercenterofboston.com

The Cancer Center of Boston was established in September 1986 by Jacob J. Lokich, MD and Murray M. Bern, MD, formerly the chiefs of medical oncology and hematology, respectively, at the New England Deaconess Hospital. Their collaboration was based on the desire to develop a network of community based, freestanding facilities to diagnose and treat cancer and hematologic diseases with state-of-the-art therapies and access to clinical trials. Over the ensuing decade, the Boston facility has been expanded to include facilities or programs in Arlington (1987), Plymouth (1991) and Framingham (1994). In 2005, The Cancer Center relocated the Boston office to Chestnut Hill. Community based referrals are complemented by referrals from families and patients representing approximately 50% of all new patients. We see patients from regional, national and international locales, in part because of special areas of expertise such as infusion chemotherapy and participation on national and international clinical trial panels.

Recent Publications by Cancer Center of Boston:



- [Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma.](#)
*OBJECTIVES: To determine if "same day" Pegfilgrastim (Pf) with CHOP...*10th August, 2006
The Cancer Center of Boston, Chestnut Hill, MA, USA.- *Am J Clin Oncol.* 2006 Aug;29(4):361-3. ([DOI](#) [Direct Link](#))
- [Same-day pegfilgrastim and chemotherapy.](#)
*Pegylated filgrastim is a new formulation of a neutrophil...*7th January, 2006
The Cancer Center of Boston in Boston, Plymouth, and Framingham,- *Cancer Invest.* 2005;23(7):573-6. ([DOI](#) [Direct Link](#))
- [Coagulopathy, following medical therapy, for carcinoma of the prostate.](#)
*Cancer of the prostate can be associated with coagulopathy characterized...*8th October, 2005
The Cancer Center of Boston, Boston, MA 02120, USA.- *Hematology.* 2005 Feb;10(1):65-8. ([DOI](#)

[Direct Link](#))

- [Treatment of factor XI inhibitor using recombinant activated factor VIIa.](#)
*A 30-year-old female with severe factor XI deficiency of 0-2% acquired...*26th May, 2005
The Cancer Center of Boston, The New England Baptist Hospital, Harvard- Haemophilia. 2005 Jan;11(1):20-5. ([DOI Direct Link](#))
- [Tumor response and survival end points in clinical trials: a clinician's perspective.](#)
*Survival has become the gold standard for determining the relative...*29th April, 2005
The Cancer Center of Boston, Boston, Massachusetts 02120, USA.- Am J Clin Oncol. 2004 Oct;27(5):494-6.
- [Observations on possible effects of daily vitamin K replacement, especially upon warfarin therapy.](#)
*Daily parenteral vitamin K supplement is now recommended by the U.S. Food...*9th April, 2005
Cancer Center of Boston, New England Baptist Hospital, Harvard Medical- JPEN J Parenter Enteral Nutr. 2004 Nov-Dec;28(6):388-98.
- [Capecitabine: fixed daily dose and continuous \(noncyclic\) dosing schedule.](#)
*BACKGROUND: Oral fluoropyrimidines are presumed to emulate a parenteral...*30th December, 2004
The Cancer Center of Boston, Boston, Massachusetts, USA.- Cancer Invest. 2004;22(5):713-7.
- [Cutaneous hand and foot toxicity associated with cancer chemotherapy.](#)
*The purpose was to determine the optimal multifractionated (MF) dosing...*20th February, 2004
The Cancer Center of Boston in Boston, Massachusetts 02120, USA.- Am J Clin Oncol. 2003 Oct;26(5):435-6. ([DOI Direct Link](#))
- [Alternating doublets: establishing the optimal multifractionated dosing schedule to administer docetaxel, cisplatin, gemcitabine, and vinorelbine in combination.](#)
*The purpose was to determine the optimal multifractionated (MF) dosing...*5th February, 2004
Cancer Center of Boston, 125 Parker Hill Ave., Boston, Plymouth, MA- Cancer Invest. 2003;21(6):830-6.
- [Very low dose warfarin as prophylaxis against ultrasound detected deep vein thrombosis following primary hip replacement.](#)
*One mg daily warfarin was compared to variable dose warfarin (PT 1.3-1.5...*26th November, 2002
The Cancer Center of Boston, Boston, Massachusetts, USA.- Am J Hematol. 2002 Oct;71(2):69-74. ([DOI Direct Link](#))

Press Releases on Cancer Center of Boston:

River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries	21st November, 2009	American Society of Tropical Medicine and Hygiene	WASHINGTON, Nov. 21 /PRNewswire-USNewswire/ -- A regional initiative launched in the 1990s to eliminate onchocerciasis (river blindness) in the Americas has substantially reduced the prevalence of the
SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs to Know About Mammograms'	20th November, 2009	SIRIUS XM Radio	NEW YORK, Nov. 20 /PRNewswire-FirstCall/ -- SIRIUS XM Radio (Nasdaq: SIRI) today announced that it will broadcast Doctor Radio Reports: What Every Women Needs to Know About Mammograms, an in-depth

Senate Health Bill Raises Taxes on Families of Special Needs Children	20th November, 2009	Americans for Tax Reform	WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- There are 18 separate tax hikes in the Reid-Obama healthcare bill. One of them caps the amount that can be deferred in Flexible Spending Accounts (FSAs)
Half of Eligible Patients Do Not Get Aortic Valve Replacement	20th November, 2009	University of Michigan Health System	ANN ARBOR, Mich., Nov. 20 /PRNewswire-USNewswire/ -- Fear about the risk of surgery is among the reasons half of eligible patients are not getting aortic valve replacement surgery, according to a
Susan G. Komen for the Cure's Nancy Brinker to Grapple with New Guidelines for Breast Cancer Screening, Mon., Nov. 23	20th November, 2009	National Press Club	WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Ambassador Nancy G. Brinker, founding chair of Susan G. Komen for the Cure, will address the controversy over new federal breast cancer screening

BioNews Results for Cancer Center of Boston



- [Jury Still Out on Whether Advanced Technology Can Improve the Outcomes of Patients With Anal Canal Cancer](#)
Cancernetwork.com: Nov 15 2009 1:11AM Matching: cancer center boston
- [Dana-Farber Cancer Institute Selects Plateau Systems' Integrated Talent Management Suite](#)
Media Newswire: Nov 13 2009 6:58AM Matching: cancer center boston
- [OXiGENE to Present at American Society of Hematology and AACR/NCI/EORTC Meetings](#)
Pharmacy Choice: Nov 13 2009 6:25AM Matching: cancer center boston
- [Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to Be Presented at the 2009 AACR-NCI-EORTC Int](#)
Pharmacy Choice: Nov 13 2009 6:26AM Matching: cancer center boston
- [Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to Be Presented at the 2009 AACR-NCI-EORTC Int](#)
Genetic Engineering News: Nov 13 2009 12:13AM Matching: cancer center boston
- [Aspirin shows promise for colon cancer patients](#)
WTVM: Nov 12 2009 9:21AM Matching: cancer center boston
- [Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to Be Presented at the 2009 AACR-NCI-EORTC Int](#)
Yahoo! Canada: Nov 12 2009 9:04PM Matching: cancer center boston
- [Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to Be Presented at the 2009 AACR-NCI](#)
Interest!ALERT: Nov 12 2009 9:32PM Matching: cancer center boston
- [Nodal Staging Score: A Tool to Assess Adequate Staging of Node-Negative Colon Cancer \[Gastrointestinal Cancer\]](#)

- Journal of Clinical Oncology: Nov 11 2009 8:40PM Matching: cancer center boston*
- [Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer,](#)
Journal of Clinical Oncology: Nov 11 2009 8:39PM Matching: cancer center boston
 - [Poniard Pharmaceuticals to Present Updated Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer](#)
Pharma Live: Nov 11 2009 4:47AM Matching: cancer center boston
 - [Conjugated Equine Estrogen Influence on Mammographic Density in Postmenopausal Women in a Substudy of the Wome](#)
Journal of Clinical Oncology: Nov 11 2009 8:38PM Matching: cancer center boston
 - [Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Lef](#)
Journal of Clinical Oncology: Nov 11 2009 8:38PM Matching: cancer center boston
 - [Right Brains Wanted: Sanofi-Aventis Wants to Tap the Creative Genius of Boston-Area Biotechs](#)
Xconomy: Nov 11 2009 5:39AM Matching: cancer center boston
 - [Sunesis to Present Nonclinical Voreloxin Combination Data at AACR-EORTC-NCI Conference](#)
Pharma Live: Nov 11 2009 4:48AM Matching: cancer center boston

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,
Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

